London
Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings.
Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms; Fc modified antibodies have shown to augment the various immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule
To order this 250+ page report, which features 100+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Key Market Insights
The Fc engineered antibodies pipeline features more than 125 marketed drugs / drug development programs
Around 15% Fc protein and glyco-engineered antibodies are marketed, while close to 75% are being evaluated in different phases of clinical trials and 10% in preclinical studies. Examples of marketed Fc engineered antibodies include Gazvya®, Imfinzi®, MONJUVI® and Skyrizi®.
Close to 6,500 patents have been filed / granted for Fc protein and glyco-engineered antibodies, since 2016
Around 30% of these intellectual property documents were filed / granted in the Asia-Pacific; with maximum number of patents filed in Australia. This is followed by North America (32%) and Europe (23%). Leading industry players (in terms of the size of intellectual property portfolio) include Roche, Janssen, Novartis, Genentech, Amgen, MacroGenics and Genmab.
To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market/request-sample.html
Key Questions Answered
§ Who are the leading industry and non-industry players engaged in the development of Fc protein and glyco-engineered antibodies?
§ Which are the key disease indications being targeted by Fc engineered antibodies?
§ Which partnership models are commonly adopted by stakeholders engaged in this domain?
§ Which geographies are the most active in conducting clinical trials on Fc protein and glyco-engineered antibodies?
§ Which are the leading administering institutes supporting the research related to Fc protein and glyco-engineered antibodies?
§ How has the intellectual property landscape in this market evolved over the years?
§ Which key factors are likely to influence the evolution of this market?
§ How is the current and future market opportunity likely to be distributed across key market segments?
For additional details, please visit
or email [email protected]
You may also be interested in the following titles:
1. TIL-based Therapies Market, 2021-2030
2. TCR-based Therapies Market, 2021-2030
3. Peptide Therapeutics Market, 2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415